Investing
Medical Concern About FDA Approval Of Genentech (DNA) Avastin
Published:
The FDA has approved Genentech’s (NYSE: DNA) drug Avastin for the treatment of breast cancer. The product is already Genentech’s top selling drug but is marketed for treating other cancers.
Tests by FDA science panels found that the drug does shrink tumors but does not extend patient life expectancy. "All they had was progression-free survival in one trial, no increase in quality of life and patient deaths in the Avastin group," said Fran Visco president of the National Breast Cancer Coalition. "We’re very confused why FDA made this decision, told MSNBC.
Genentech may be taking a product liability risk, which is not necessarily good for its shareholders. In the trial study of the drug which was submitted to the FDA "six deaths attributed to the drug."
Genentech had better hope that those causalities were an aberration.
Douglas A. McIntyre
Want to Retire Early? Start Here (Sponsor)
Want retirement to come a few years earlier than you’d planned? Or are you ready to retire now, but want an extra set of eyes on your finances?
Now you can speak with up to 3 financial experts in your area for FREE. By simply clicking here you can begin to match with financial professionals who can help you build your plan to retire early. And the best part? The first conversation with them is free.
Click here to match with up to 3 financial pros who would be excited to help you make financial decisions.
Have questions about retirement or personal finance? Email us at [email protected]!
By emailing your questions to 24/7 Wall St., you agree to have them published anonymously on a673b.bigscoots-temp.com.
By submitting your story, you understand and agree that we may use your story, or versions of it, in all media and platforms, including via third parties.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
